Profile data is unavailable for this security.
About the company
Sakar Healthcare Limited is an India-based company, which is engaged in the manufacturing of pharmaceutical products. The Company is engaged in providing liquid orals, cephalosporin tablets, capsules, dry powder syrup, dry powder injections, liquid injectables (SVP) in ampoules, vials and lyophilized injections, oral solid dosages, and research and development of these products. The Company’s products include Oral - Liquid Syrup & Suspension, Liquid Injectable (SVP)-Vials & Ampoules, Cephalosporin - Dry Powder Injections, Cephalosporin - Oral Solid and Lyophilised Injections (In Vials). The Company operates as a contract development and manufacturing organization (CDMO). The Company has approximately 321 product registrations in various countries. The manufacturing unit has been accredited by regulatory authorities of 14 countries, which includes Uganda, Kenya, Yemen, Ethiopia, Congo, Zimbabwe, Nigeria, Malawi, Philippines, Peru, Vietnam, Cote D’Ivoire.
- Revenue in INR (TTM)1.51bn
- Net income in INR124.73m
- Incorporated2004
- Employees297.00
- LocationSakar Healthcare Ltd406,Silver Oaks Comm. Complex,Opp. Arun Society, PaldiAHMEDABAD 380007IndiaIND
- Phone+91 7 926584655
- Fax+91 2 717251621
- Websitehttp://www.sakarhealthcare.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Kilitch Drugs (India) Ltd | 1.55bn | 145.71m | 5.52bn | 153.00 | 37.24 | -- | 34.21 | 3.56 | 9.21 | 9.21 | 98.24 | -- | -- | -- | -- | 10,132,730.00 | -- | 2.63 | -- | 3.59 | 39.68 | 33.85 | 8.25 | 5.01 | -- | 3.43 | -- | 2.93 | 22.20 | 22.30 | 41.82 | 15.19 | 1.79 | -- |
ZIM Laboratories Ltd | 3.67bn | 172.46m | 5.53bn | 525.00 | 32.08 | 2.32 | 16.65 | 1.50 | 3.54 | 3.54 | 75.34 | 49.00 | 0.9321 | 2.54 | 3.76 | -- | 4.38 | 3.88 | 6.66 | 6.54 | 53.34 | 48.30 | 4.69 | 3.97 | 0.9182 | 3.67 | 0.3131 | -- | -7.80 | 1.84 | -29.42 | 2.37 | 29.41 | -- |
Valiant Laboratories Ltd | -100.00bn | -100.00bn | 6.18bn | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 60.35 | -- | 27.66 | -- | -- | -- |
IND Swift Laboratories Ltd | 12.81bn | 3.07bn | 6.60bn | 1.50k | 2.15 | 0.7089 | 1.83 | 0.5155 | 51.99 | 51.99 | 216.90 | 157.64 | 0.857 | 3.45 | 3.80 | -- | 20.58 | 5.00 | 25.67 | 6.13 | 39.47 | 42.82 | 24.02 | 8.52 | 2.94 | 1.70 | 0.0175 | -- | 6.10 | 11.10 | 784.44 | 70.82 | 23.60 | -- |
Medicamen Biotech Ltd | 1.71bn | 126.93m | 6.63bn | 388.00 | 53.35 | -- | 36.53 | 3.89 | 9.78 | 9.78 | 131.89 | -- | -- | -- | -- | 4,398,250.00 | -- | 7.17 | -- | 10.44 | 46.88 | 33.85 | 6.58 | 10.87 | -- | 4.76 | -- | 8.61 | 22.02 | 4.77 | -0.3555 | 7.98 | -4.21 | 0.00 |
Albert David Ltd | 3.62bn | 754.20m | 6.68bn | 1.27k | 8.86 | 1.74 | 8.12 | 1.84 | 132.16 | 132.16 | 635.16 | 671.05 | 0.7868 | 2.67 | 12.15 | -- | 16.37 | 10.00 | 20.85 | 13.15 | 65.30 | 61.03 | 20.81 | 11.87 | 3.31 | 124.70 | 0.0086 | 12.89 | 6.12 | 2.72 | 108.49 | 33.59 | 40.87 | 13.90 |
Sakar Healthcare Ltd | 1.51bn | 124.73m | 7.50bn | 297.00 | 56.55 | -- | 25.69 | 4.97 | 6.10 | 6.10 | 73.58 | -- | -- | -- | -- | 5,082,286.00 | -- | 6.35 | -- | 7.59 | 46.18 | 44.28 | 8.26 | 10.84 | -- | 2.40 | -- | -- | 4.00 | 20.23 | -16.30 | 27.31 | 56.31 | -- |
Nectar Lifesciences Ltd | 16.86bn | 49.95m | 7.67bn | 1.59k | 148.70 | 0.7173 | 11.67 | 0.455 | 0.23 | 0.23 | 79.16 | 47.68 | 0.7697 | 1.74 | 5.12 | -- | 0.228 | -0.2956 | 0.3969 | -0.541 | 28.68 | 18.39 | 0.2963 | -0.4052 | 0.5907 | 1.06 | 0.3728 | -- | 10.63 | -9.54 | 120.65 | -36.29 | -5.06 | -- |
Panacea Biotec Ltd | 5.52bn | -119.17m | 8.34bn | 1.09k | -- | -- | 16.22 | 1.51 | -1.89 | -1.89 | 89.86 | -- | -- | -- | -- | 5,046,990.00 | -- | 10.52 | -- | 18.65 | 56.88 | 50.87 | -2.21 | 27.34 | -- | -- | -- | 0.00 | -30.44 | -5.06 | -103.08 | -- | 21.89 | -- |
Bajaj Healthcare Ltd | 4.98bn | 212.66m | 8.52bn | 1.06k | 40.03 | -- | 17.38 | 1.71 | 7.71 | -18.22 | 180.50 | -- | -- | -- | -- | 4,684,510.00 | -- | 9.86 | -- | 17.42 | 42.26 | 26.47 | 4.27 | 8.57 | -- | 1.66 | -- | -- | -0.9704 | 15.53 | -39.73 | 23.16 | 60.82 | 31.95 |
Jagsonpal Pharmaceuticals Ltd | 2.21bn | 245.16m | 8.96bn | 940.00 | 36.45 | -- | 34.12 | 4.06 | 9.30 | 9.30 | 83.51 | -- | -- | -- | -- | 2,347,522.00 | -- | 10.02 | -- | 12.51 | 54.09 | 58.47 | 11.11 | 8.03 | -- | 30.39 | -- | 36.24 | 8.79 | 13.33 | 41.72 | -- | -39.20 | 118.67 |
Holder | Shares | % Held |
---|---|---|
HBM Partners AG (Investment Management)as of 31 Dec 2023 | 1.50m | 6.90% |